Two Year SAVE Outcomes: 2.0 mg Ranibizumab for Recalcitrant Neovascular AMD
The Super-dose Anti-VEGF (SAVE) trial assessed the efficacy of 2.0 mg ranibizumab (0.05 ml), a 4-fold higher dose than the 0.5 mg dose approved by the US Food and Drug Administration, for the management of recalcitrant neovascular age-related macular degeneration (AMD) in 88 patients. Primary outcome results of the 3-month, fixed-interval dosing period were reported in Ophthalmology, and in this report we offer 2-year follow-up data.